Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say

Core Insights - Amneal Pharmaceuticals reported revenue of $784.51 million for the quarter ended September 2025, reflecting an 11.7% increase year-over-year and a surprise of +1.41% over the Zacks Consensus Estimate of $773.6 million [1] - The company's EPS for the quarter was $0.17, up from $0.16 in the same quarter last year, resulting in a surprise of +30.77% compared to the consensus EPS estimate of $0.13 [1] Revenue Breakdown - Affordable Medicines Segment generated net revenue of $460.74 million, slightly below the estimated $465.18 million, but still showing a year-over-year increase of +7.8% [4] - AvKARE Segment reported net revenue of $198.53 million, exceeding the average estimate of $192.83 million, with a significant year-over-year growth of +24.5% [4] - Specialty Segment achieved net revenue of $125.24 million, surpassing the average estimate of $114.52 million, marking an +8.3% increase year-over-year [4] Stock Performance - Over the past month, Amneal's shares have returned +0.5%, while the Zacks S&P 500 composite has seen a +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]